Home / Markets / Industries / Health Care

Monday, August 31, 2009

Delcath Systems Gets Orphan Status For Liver Cancer Treatment (DCTH)

Comtex

Aug 31, 2009 (SmarTrend(R) News Watch via COMTEX) ----8/31/2009 - Delcath Systems Inc. (NASDAQ:DCTH) announced Monday that the FDA gave orphan status to the company's developing liver cancer treatment doxorubicin. Orphan status is given to drugs that are aimed at rare conditions or conditions that have a lack of treatments on the market. The benefits of the status include seven years of market exclusivity following FDA approval, assistance in clinical trial design, a reduction in user fees, and tax credits. The company focuses on using drug delivery technology that gives ultra-high doses of anticancer drugs to the liver.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

Copyright, Comtex News Network, Inc. 2009

Fox Business Video

- The Crisis With 20/20 Hindsight
- Nov 21, 2009
  
  FOXBusiness.com LIVE
- Jerry Rice Talks Career
- Nov 21, 2009
  
  NFL Receiver on career on the gridiron
- John O'Hurley as Venture Capitalist
- Nov 21, 2009
  
  Comedian on life as venture capitalist
- Excess Spending in Congress
- Nov 21, 2009
  
  Saving $100 Million
- Cavuto Business Report 11-20-09
- Nov 21, 2009
  
  Business Report: Cavuto